Voyager Therapeutics (VYGR) Competitors

$3.66 +0.17 (+4.71%)

Closing price 03:59 PM Eastern

Extended Trading

$3.68 +0.02 (+0.41%)

As of 04:10 PM Eastern

VYGR vs. DSGN, SDGR, MGTX, SANA, and ANNX

Should you buy Voyager Therapeutics stock or one of its competitors? MarketBeat compares Voyager Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Voyager Therapeutics include Design Therapeutics (DSGN), Schrodinger (SDGR), MeiraGTx (MGTX), Sana Biotechnology (SANA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

How does Voyager Therapeutics compare to Design Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Design Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.49	-$119.72M	-$1.97	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 350.20%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 49.80%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Design Therapeutics had 11 more articles in the media than Voyager Therapeutics. MarketBeat recorded 12 mentions for Design Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Design Therapeutics' score of 0.36 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Voyager Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Design Therapeutics' return on equity of -33.07% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Design Therapeutics	N/A	-33.07%	-31.29%

Summary

Design Therapeutics beats Voyager Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Schrodinger?

Voyager Therapeutics (NASDAQ:VYGR) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Schrodinger has higher revenue and earnings than Voyager Therapeutics. Schrodinger is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.49	-$119.72M	-$1.97	N/A
Schrodinger	$255.87M	3.82	-$103.26M	-$1.41	N/A

Schrodinger has a net margin of -40.61% compared to Voyager Therapeutics' net margin of -319.61%. Schrodinger's return on equity of -30.85% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Schrodinger	-40.61%	-30.85%	-15.32%

Voyager Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 350.20%. Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 53.07%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Voyager Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Schrodinger had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 5 mentions for Schrodinger and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Schrodinger's score of -0.30 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Schrodinger beats Voyager Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, MeiraGTx had 7 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for MeiraGTx and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat MeiraGTx's score of 0.40 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

MeiraGTx presently has a consensus price target of $25.83, suggesting a potential upside of 172.10%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 350.20%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

MeiraGTx has a net margin of -151.12% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

MeiraGTx has higher revenue and earnings than Voyager Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.80	-$114.20M	-$1.48	N/A
Voyager Therapeutics	$40.37M	5.49	-$119.72M	-$1.97	N/A

Summary

MeiraGTx beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sana Biotechnology currently has a consensus price target of $9.50, indicating a potential upside of 200.35%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 350.20%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Sana Biotechnology has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Sana Biotechnology has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, Sana Biotechnology had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 5 mentions for Sana Biotechnology and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Sana Biotechnology's score of -0.14 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Voyager Therapeutics	$40.37M	5.49	-$119.72M	-$1.97	N/A

Summary

Sana Biotechnology and Voyager Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Annexon?

Voyager Therapeutics (NASDAQ:VYGR) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 350.20%. Annexon has a consensus price target of $16.00, indicating a potential upside of 194.33%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Voyager Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Voyager Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Annexon has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Annexon had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Annexon and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Annexon's score of 0.72 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.49	-$119.72M	-$1.97	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Voyager Therapeutics beats Annexon on 12 of the 16 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221.44M	$3.36B	$6.34B	$12.28B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-1.86	19.02	20.92	25.48
Price / Sales	5.49	278.81	521.15	73.33
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.28	6.90	9.98	7.01
Net Income	-$119.72M	$24.23M	$3.55B	$335.16M
7 Day Performance	-13.56%	0.65%	0.40%	-0.30%
1 Month Performance	-11.04%	-0.55%	-0.04%	1.14%
1 Year Performance	16.35%	63.42%	34.95%	34.69%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	2.8708 of 5 stars	$3.67 +4.7%	$16.50 +350.2%	+2.9%	$221.44M	$40.37M	N/A	100
DSGN Design Therapeutics	3.3216 of 5 stars	$10.70 -25.5%	$16.50 +54.2%	+202.5%	$897.51M	N/A	N/A	40	Options Volume Gap Up High Trading Volume
SDGR Schrodinger	2.7892 of 5 stars	$12.05 +0.8%	$20.25 +68.0%	-42.8%	$882.21M	$255.87M	N/A	790
MGTX MeiraGTx	2.9685 of 5 stars	$9.40 flat	$25.83 +174.8%	+74.2%	$870.53M	$81.39M	N/A	300	News Coverage Earnings Report Insider Trade
SANA Sana Biotechnology	2.6169 of 5 stars	$3.04 -1.0%	$9.50 +212.5%	+48.8%	$854.35M	N/A	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. DSGN, SDGR, MGTX, SANA, and ANNX

How does Voyager Therapeutics compare to Design Therapeutics?

Summary

How does Voyager Therapeutics compare to Schrodinger?

Summary

How does Voyager Therapeutics compare to MeiraGTx?

Summary

How does Voyager Therapeutics compare to Sana Biotechnology?

Summary

How does Voyager Therapeutics compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. DSGN, SDGR, MGTX, SANA, and ANNX

How does Voyager Therapeutics compare to Design Therapeutics?

Which has preferable valuation and earnings, VYGR or DSGN?

Do analysts prefer VYGR or DSGN?

Do institutionals & insiders hold more shares of VYGR or DSGN?

Does the media favor VYGR or DSGN?

Which has more volatility & risk, VYGR or DSGN?

Is VYGR or DSGN more profitable?

Summary

How does Voyager Therapeutics compare to Schrodinger?

Which has higher earnings & valuation, VYGR or SDGR?

Is VYGR or SDGR more profitable?

Which has more volatility and risk, VYGR or SDGR?

Do institutionals and insiders have more ownership in VYGR or SDGR?

Do analysts prefer VYGR or SDGR?

Does the media refer more to VYGR or SDGR?

Summary

How does Voyager Therapeutics compare to MeiraGTx?

Does the media favor MGTX or VYGR?

Do insiders & institutionals hold more shares of MGTX or VYGR?

Which has more risk & volatility, MGTX or VYGR?

Do analysts rate MGTX or VYGR?

Is MGTX or VYGR more profitable?

Which has higher earnings & valuation, MGTX or VYGR?

Summary

How does Voyager Therapeutics compare to Sana Biotechnology?

Do institutionals & insiders believe in SANA or VYGR?

Do analysts prefer SANA or VYGR?

Is SANA or VYGR more profitable?

Which has more risk & volatility, SANA or VYGR?

Does the media favor SANA or VYGR?

Which has higher valuation & earnings, SANA or VYGR?

Summary

How does Voyager Therapeutics compare to Annexon?

Do analysts recommend VYGR or ANNX?

Which has more risk and volatility, VYGR or ANNX?

Is VYGR or ANNX more profitable?

Does the media favor VYGR or ANNX?

Which has stronger earnings & valuation, VYGR or ANNX?

Do insiders and institutionals believe in VYGR or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools